About Carnabio
Carnabio is a publicly listed company based in Kobe (Japan) founded in 2003. It develops kinase assay kits and provides services in protein characterization. The company has 63 employees. Its website carnabio.com draws about 21 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery.
Company details
Carna Biosciences engages in developing protein kinase assays such as lipid Kinase, Serinethreonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, and biotinylated kinase. Other products offered are substrates for kinase assay and stable cell line. The company also provides following services profiling, protein-protein interaction, live cell kinase assay, cell-based assay, crystallography, and custom production of ultra-pure proteins for crystallography.
- Headquarters Kobe, Japan
- Employees 63
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website carnabio.com
- Social LinkedIn
- Legal Name Carna Biosciences, Inc.
- Annual Revenue$3.7 M (USD)-8.99as on Dec 31, 2025
- Net Profit-$13.85 M (USD)0.33as on Dec 31, 2025
- EBITDA-$13.21 M (USD)-1.47as on Dec 31, 2025
- Employee Count63
IPO & Listings of Carnabio
Carnabio is a publicly listed company on the TSE with ticker symbol 4572 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2013
- Listed onTSE: 4572
- Listed entityCarna Biosciences, Inc.
- Exchange sectorHealth technology
- ISINJP3220550002
- Share price343.00 JPY (-4.99% on the day) · 2026-10-14
- Market capitalisation7,695,004,385.00 JPY
- EPS (diluted, trailing year)-111.45 JPY
- Volume (last session)176,000
Financials of Carnabio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 579.1M JPY | -2.17B JPY | -2.07B JPY |
| 2024 | 636.2M JPY | -2.18B JPY | -2.04B JPY |
| 2023 | 1.63B JPY | -1.15B JPY | -1.08B JPY |
| 2022 | 1.39B JPY | -1.35B JPY | -1.24B JPY |
| 2021 | 2.02B JPY | -534.5M JPY | -512.0M JPY |
Detailed financial statements for Carnabio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Carnabio
The website of Carnabio (carnabio.com) receives about 21.3K visits a month and ranks #1,167,012 among all websites worldwide, #1,459 in Biotechnology and Pharmaceuticals.
- Monthly visits21.3K
▼ 4.5% vs previous month
- Unique visitors8.1K
per month
- Global rank#1,167,012
among all websites
- Category rank#1,459
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.3
- Average visit47 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Carnabio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tokiwaph.co.jp | tokiwaph.co.jp | 100% | #1,089,792 | – | |
| rtechueno.com | 80% | View details | |||
bioteclab.co.jp | bioteclab.co.jp | 78% | #5,470,117 | – | |
| dwti.co.jp | 76% | 7.6K | #2,755,146 | View details | |
| prismbiolab.com | 74% | 8.6K | #2,302,849 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Carnabio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Carnabio
Complete news archive for Carnabio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carnabio
Carnabio was founded in 2003.
Carnabio is headquartered in Kobe, Japan. It is registered at Kobe, Hyogo, Japan.
Carnabio has 63 employees.
Annual revenue of Carnabio is $3.7M as on Dec 31, 2025.
Carna Biosciences engages in developing protein kinase assays such as lipid Kinase, Serinethreonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, and biotinylated kinase. Other products offered are substrates for kinase assay and stable cell line. The company also provides following services profiling, protein-protein interaction, live cell kinase assay, cell-based assay, crystallography, and custom production of ultra-pure proteins for crystallography.
Yes, Carnabio is publicly traded on TSE under the ticker symbol 4572.